Study of NX-5948 for advanced CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have CLL or SLL that has returned or not responded to treatment.
- You have already been treated with a BTK inhibitor and a BCL-2 inhibitor.
- You are able to do daily activities with little or no help (ECOG score 0-2).
- You have adequate organ and bone marrow function.
- You have not had certain other cancer treatments recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
This early-stage study tests a new drug called NX-5948, given alongside other cancer treatments, for adults with B-cell lymphomas and leukemias (including chronic lymphocytic leukemia, or CLL). The goal is to see if this combination helps control the disease, especially in patients whose cancer has come back or stopped responding to prior treatments.
This trial tests whether NX-5948 is more effective than pirtobrutinib for people with CLL or SLL whose disease has gotten worse after an earlier BTK inhibitor treatment. It aims to find a better option for those who have already tried one type of therapy.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.